SCHEMBL835284

SCHEMBL835284

Cc1ccc2c(c1)c(Sc1ccc(F)cc1)cc(=O)n2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
POLB P06746 3/20 0.43
LMNA P02545 3/20 0.43
HTR1A P08908 2/20 0.42
HTR3A P46098 2/20 0.42
KDM4E B2RXH2 4/20 0.41
PRNP P04156 1/20 0.41
NQO2 P16083 1/20 0.41
TP53 P04637 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
ATM Q13315 2/20 0.39
NTSR1 P30989 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HTT P42858 1/20 0.39
CSF1R P07333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL835001 0.92 RXFP1 (0.44) RXFP1MEN1KMT2APOLBLMNA
SCHEMBL836066 0.92 RXFP1 (0.48) RXFP1MEN1KMT2APOLBLMNA
SCHEMBL835002 0.90 RXFP1 (0.45) RXFP1MEN1KMT2APOLBLMNA
SCHEMBL835287 0.86 RXFP1 (0.43) RXFP1MEN1KMT2APOLBLMNA
SCHEMBL836059 0.86 RHEB (0.50) RXFP1MEN1KMT2APOLBLMNA
SCHEMBL829660 0.86 MEN1 (0.43) RXFP1MEN1KMT2APOLBLMNA
SCHEMBL14302623 0.86 LMNA (0.43) RXFP1MEN1KMT2APOLBLMNA
SCHEMBL835229 0.85 NQO2 (0.42) RXFP1POLBLMNAHTR1AHTR3A
SCHEMBL836028 0.85 KDM4E (0.51) RXFP1MEN1KMT2APOLBLMNA
SCHEMBL14302622 0.84 LMNA (0.41) RXFP1MEN1KMT2APOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds GTF3C4, HNF4A, TENT4A RXFP1 4782/4885MEN1 3979/4885KMT2A 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.